Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab versus adalimumab and placebo for induction of remission in TNF inhibitor-naive moderate to severe ulcerative colitis
2013-004279-11Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab, Adalimumab and Placebo (3 arms). Primary endpoint: Induction of remission compared with placebo as determined by the Mayo Clinic Score. Started Sep 2014; status: completed.
02
Drugs
Etrolizumabadalimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004279-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004279-11.